Cetirizine Hydrochloride, a minuscule molecule with a multifaceted pharmacological profile, operates as a potent and selective H1 receptor antagonist. Its primary utility lies in the treatment of allergic conjunctivitis, chronic urticaria, allergic rhinitis, and urticaria, maladies that plague a significant number of individuals globally. By bonding to the H1 receptor, it functions as a competitive antagonist that counteracts the deleterious effects of histamine, an endogenous substance that triggers allergy symptoms such as pruritus, sneezing, and rhinorrhea. Approved in 1991, Cetirizine Hydrochloride was brought into existence by the pharmaceutical behemoth Johnson & Johnson, and its wide-ranging clinical applications have earned it a reputation as a potent allergy-fighting tool, particularly for those with seasonal allergies. It is available in a plethora of dosage forms, including tablets, syrups, and topical creams, catering to the diverse needs of allergy sufferers worldwide. Click on the image below to begin the exploration journey of Cetirizine through the Synapse database!
You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!